- Completion of Estelle® Phase III US/Canada study of Estelle® phase III programme completes
Mithra’s most advanced clinical programme
- EU/Russia study reported positive results achieving primary and secondary endpoints
- Estelle® Phase III study in US/Canada will report top-line results in Q1 2019
- Estelle® : a step closer to become next generation COC on the market
Liège, Belgium, 14 November 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of the Phase III Estelle® study in the US and Canada. Estelle® is Mithra’s novel combined oral contraceptive (COC), containing 15 mg Estetrol (E4)/3 mg drospirenone (DRSP). Top line data remain on track to be reported in Q1 2019.